abcam

Product datasheet

Recombinant Human HtrA2 / Omi protein ab48747

1 Image

Description

Product name Recombinant Human HtrA2 / Omi protein

Purity > 95 % SDS-PAGE.

The mature HtrA2/Omi protein (134-458aa) was overexpressed in E.coli and purified by

conventional column chromatography techniques.

Expression system Escherichia coli

Protein length Full length protein

Animal free No

Nature Recombinant

Species Human

Sequence MAVPSPPPAS PRSQYNFIAD VVEKTAPAVV YIEILDRHPF

LGREVPISNG SGFVVAADGL IVTNAHVVAD

RRRVRVRLLS GDTYEAVVTA VDPVADIATL RIQTKEPLPT

LPLGRSADVR QGEFVVAMGS PFALQNTITS GIVSSAQRPA RDLGLPQTNV EYIQTDAAID

FGNAGGPLVN LDGEVIGVNT MKVTAGISFA IPSDRLREFL HRGEKKNSSS GISGSQRRYI GVMMLTLSPS ILAELQLREP SFPDVQHGVL IHKVILGSPA HRAGLRPGDV ILAIGEQMVQ

NAEDVYEAVR TQSQLAVQIR RGRETLTLYV

TPEVTEGSHH HHHH

Specifications

Our **Abpromise guarantee** covers the use of **ab48747** in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Applications SDS-PAGE

Form Liquid

Preparation and Storage

Stability and Storage Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

pH: 8.00

Constituents: 0.0154% DTT, 0.316% Tris HCl, 20% Glycerol (glycerin, glycerine), 0.29% Sodium

General Info

Function

Serine protease that shows proteolytic activity against a non-specific substrate beta-casein. Promotes or induces cell death either by direct binding to and inhibition of BIRC proteins (also called inhibitor of apoptosis proteins, IAPs), leading to an increase in caspase activity, or by a BIRC inhibition-independent, caspase-independent and serine protease activity-dependent mechanism. Cleaves THAP5 and promotes its degradation during apoptosis. Isoform 2 seems to be proteolytically inactive.

Tissue specificity

Involvement in disease

lsoform 1 is ubiquitous. Isoform 2 is expressed predominantly in the kidney, colon and thyroid.

Defects in HTRA2 are the cause of Parkinson disease type 13 (PARK13) [MIM:610297]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.

Sequence similarities

Belongs to the peptidase S1B family. Contains 1 PDZ (DHR) domain.

Domain

The mature N-terminus is involved in the interaction with XIAP.

The PDZ domain mediates interaction with MXI2.


Post-translational modifications

Autoproteolytically activated.

Cellular localization

Mitochondrion intermembrane space. Mitochondrion membrane. Predominantly present in the intermembrane space. Released into the cytosol following apoptotic stimuli, such as UV treatment, and stimulation of mitochondria with caspase-8 truncated BID/tBID.

Images



15% SDS-PAGE gel loaded with 3 µg ab48747.

Our Abpromise to you: Quality guaranteed and expert technical support

- · Replacement or refund for products not performing as stated on the datasheet
- · Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- · We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit https://www.abcam.com/abpromise or contact our technical team.

Terms and conditions

· Guarantee only valid for products bought direct from Abcam or one of our authorized distributors